Skip to main content

PSMA-PET for individualized radiation therapy of prostate cancer

New Content Item (4)Guest Edited by Dr Pirus Ghadjar 

The advent of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging has revolutionized radiation therapy of prostate cancer.  Current radiation therapy treatment schedules for prostate cancer have been established by randomized trials using statistical risk calculations, nomograms and conventional imaging for patient characterization and treatment.  PSMA-PET bears the promise of delivering individually tailored radiation therapy for prostate cancer.  It can already be regarded as ‘practice changing’ for radiation therapy of prostate cancer, especially concerning detection and treatment of lymph node metastases, local recurrences after prior therapies and oligometastases.  However any randomized or long-term clinical data after PSMA guided radiation therapy for prostate cancer is naturally missing.  Moreover, radio-ligand therapy (RLT) is a new treatment option for metastatic castration-resistant prostate cancer patients.

The aim of this thematic series published in Radiation Oncology is to collect and present the current knowledge and limitations of PSMA-PET based radiation therapy.

  1. The goal of this study is to evaluate the status and future perspectives of clinical trials on positron emission tomography in prostate cancer for diagnostic or therapeutic as well as for surveillance purposes.

    Authors: Nikola Cihoric, Eugenia Vlaskou Badra, Alexandros Tsikkinis, Vikas Prasad, Stephanie Kroeze, Ivan Igrutinovic, Branislav Jeremic, Marcus Beck, Sebastian Zschaeck, Peter Wust and Pirus Ghadjar
    Citation: Radiation Oncology 2018 13:113
  2. 68Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative i....

    Authors: Sebastian Zschaeck, Fabian Lohaus, Marcus Beck, Gregor Habl, Stephanie Kroeze, Constantinos Zamboglou, Stefan Alexander Koerber, Jürgen Debus, Tobias Hölscher, Peter Wust, Ute Ganswindt, Alexander D. J. Baur, Klaus Zöphel, Nikola Cihoric, Matthias Guckenberger, Stephanie E. Combs…
    Citation: Radiation Oncology 2018 13:90
  3. We hypothesized that dominant intraprostatic lesions (DILs) could be depictured by multimodal imaging techniques (MRI and/or PSMA PET/CT) in patients with primary prostate cancer (PCa) and investigated possibl...

    Authors: Constantinos Zamboglou, Christina Marie Klein, Benedikt Thomann, Thomas Franz Fassbender, Hans C. Rischke, Simon Kirste, Karl Henne, Natalja Volegova-Neher, Michael Bock, Mathias Langer, Philipp T. Meyer, Dimos Baltas and Anca L. Grosu
    Citation: Radiation Oncology 2018 13:65
  4. PSMA PET/CT visualises prostate cancer residual disease or recurrence at lower PSA levels compared to conventional imaging and results in a change of treatment in a remarkable high number of patients. Radiothe...

    Authors: Nina-Sophie Schmidt-Hegemann, Wolfgang Peter Fendler, Harun Ilhan, Annika Herlemann, Alexander Buchner, Christian Stief, Chukwuka Eze, Paul Rogowski, Minglun Li, Peter Bartenstein, Ute Ganswindt and Claus Belka
    Citation: Radiation Oncology 2018 13:37
  5. 68Ga-PSMA-PET-imaging has proven to be a highly sensitive and specific diagnostic element for patients with prostate cancer (PC). Does the standard clinical target volume (CTV) cover the majority of 68Ga-PSMA-PET...

    Authors: K. Schiller, M. Devecka, T. Maurer, M. Eiber, J. Gschwend, M. Schwaiger, S. E. Combs and G. Habl
    Citation: Radiation Oncology 2018 13:36
  6. To determine the potential role of 68Ga-PSMA positron emission tomography/computed tomography (PET/CT) in radiotherapy (RT) planning for prostate cancer (PCa).

    Authors: Nina-Sophie Schmidt-Hegemann, Wolfgang Peter Fendler, Alexander Buchner, Christian Stief, Paul Rogowski, Maximilian Niyazi, Chukwuka Eze, Minglun Li, Peter Bartenstein, Claus Belka and Ute Ganswindt
    Citation: Radiation Oncology 2017 12:176
  7. By the use of PSMA positron emission tomography (PET) detection of prostate cancer lesions with a high sensitivity and specificity combined with a favorable lesion to background contrast is feasible. Therefore...

    Authors: Sebastian Zschaeck, Peter Wust, Marcus Beck, Waldemar Wlodarczyk, David Kaul, Julian Rogasch, Volker Budach, Christian Furth and Pirus Ghadjar
    Citation: Radiation Oncology 2017 12:140